Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia

被引：24

作者：

Kvirikadze, N.

Susen, M.

Vescio, T.

Kaminer, L.

Singh, K.

机构：

[1] Evanston Northwestern Healthcare, Dept Med, Evanston, IL USA

[2] Evanston Northwestern Healthcare, Dept Pharm, Evanston, IL USA

[3] Evanston Northwestern Healthcare, Dept Hematol, Evanston, IL USA

[4] Northwestern Univ, Evanston, IL USA

来源：

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES | 2006年 / 38卷 / 04期

关键词：

D O I：

10.1080/00365540500434687

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The best therapeutic options for serious infections due to vancomyci resistant Enterococcus (VRE) remain unclear. We describe the successful treatment of vancomycin resistant Enterococcus faecium bacteremia in 2 patients using daptomycin. We also briefly review the literature on antibiotic options for VRE infection including the use of daptomycin.

引用

收藏

页码：290 / 292

页数：3

相关论文

共 20 条

[1] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].

Arbeit, RD ;

Maki, D ;

Tally, FP ;

Campanaro, E ;

Eisenstein, BI .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681

[2]

BIRMINGHAM MC, 1999, 39 INT C ANT AG CHEM

[3] Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium [J].

Caron, F ;

Gold, HS ;

Wennersten, CB ;

Farris, MG ;

Moellering, RC ;

Eliopoulos, GM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) :2749-2753

[4] Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens [J].

Carpenter, CF ;

Chambers, HF .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :994-1000

[5] Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections [J].

Chien, JW ;

Kucia, ML ;

Salata, RA .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :146-151

[6]

*CLSINCCLS, 2005, M100S15 CLSINCCLS

[7] Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality [J].

Edmond, MB ;

Ober, JF ;

Dawson, JD ;

Weinbaum, DL ;

Wenzel, RP .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (06) :1234-1239

[8] Quinupristin-dalfopristin and linezolid: Evidence and opinion [J].

Eliopoulos, GM .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) :473-481

[9] Vancomycin-resistant enterococci: Mechanisms and clinical observations [J].

Gold, HS .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) :210-219

[10] Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid [J].

Gonzales, RD ;

Schreckenberger, PC ;

Graham, MB ;

Kelkar, S ;

DenBesten, K ;

Quinn, JP .

LANCET, 2001, 357 (9263) :1179-1179